Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure (Visit 1).~* Having completed the DB study treatment and the run-out period of ID-078A301 (NCT03545191) or ID-078A302 (NCT03575104).~* For woman of childbearing potential, the following is required:~  * Negative urine pregnancy test (EOT of ID-078A301 or ID-078A302 studies)~ * Agreement to use the contraception scheme as required by the protocol from Visit 1 up to at least 30 days after EODBT.~Exclusion Criteria:~* Unstable medical condition, significant medical disorder or acute illness, C-SSRS©, ECG, hematology or biochemistry test results in ID-078A301 and ID-078A302, which in the opinion of the investigator could affect the subject's safety or interfere with the study assessments (Visit 1).~* For female subjects: lactating or planning to become pregnant during the duration of the study (Visit 1).~* Positive urine drug test (for benzodiazepines, barbiturates, cannabinoids, opiates, amphetamines, or cocaine) or presence of alcohol in exhaled breath as detected by breathalyzer test (EOT of ID-078A301 or ID-078A302 studies if same day as Visit 1 or Visit 1 if within 7 days after EOT).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daridorexant 10 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening
- Daridorexant 25 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening
- Daridorexant 50 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening
- Placebo (Type: PLACEBO_COMPARATOR): Film-coated tablets administered orally, once daily in the evening
- Ex-Placebo Daridorexant 25 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).